Amarin Corp Plc (AMRN)

[rafunrafun]

I asked Viet Le, an investigator of EVAPORATE:

Please help me answer the following:

Did EVAPORATE show that EPA reduces plaque or did it only show that EPA slows the progression of plaque?

Thank you in advance and congrats!

He replied with:

In this case the data from baseline to 18 month scan:
EPA group -0.3+/-1.5mm; Placebo group +0.9+/-1.7mm. So, by this, the fig 1 percentages can be a little confusing. There were some on statin that had plaque regression to -0.8 mm. We know this happens.

On the other side, there were those on EPA that did have some progression of plaque up to 1.2 mm. In comparison with placebo, as much as 2.6 mm, this would be slowing of progression. It speaks to the mechanism but also individual variability on high dose EPA

On the other side, there were those on EPA that did have some progression of plaque up to 1.2 mm. In comparison with placebo, as much as 2.6 mm, this would be slowing of progression. It speaks to the mechanism but also individual variability on high dose EPA

— Viet Le DMSc PA-C FACC FAHA HF-Cert (@VietHeartPA) September 1, 2020